Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy October 7, 2025 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo's expectations and plans regarding its current product candidates and programs, including statements regarding the structure of and timelines for ...